Pre-launch · We're opening Reserve Meds to a limited first cohort. Join the waitlist ›
Home / Drugs / Abecma

Abecma, idecabtagene vicleucel

Named-patient access overview. Abecma is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.

About Abecma

Abecma (idecabtagene vicleucel) is manufactured by BMS/2seventy and indicated for Multiple myeloma. It is a CAR-T (BCMA) approved by the US FDA in 2021 and may be accessible to international patients through Named Patient Program or personal-import pathways.

How Reserve Meds coordinates Abecma

  1. Patient or treating physician submits a named-patient request.
  2. Clinical team verifies appropriateness of Abecma for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific NPP / personal-import documentation is prepared.
  5. Abecma is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Abecma in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Abecma in BahrainFull deep-dive on regulatory pathway, costs, timing Abecma in EgyptFull deep-dive on regulatory pathway, costs, timing Abecma in IndiaFull deep-dive on regulatory pathway, costs, timing Abecma in JordanFull deep-dive on regulatory pathway, costs, timing Abecma in KuwaitFull deep-dive on regulatory pathway, costs, timing Abecma in PakistanFull deep-dive on regulatory pathway, costs, timing Abecma in QatarFull deep-dive on regulatory pathway, costs, timing Abecma in TurkeyFull deep-dive on regulatory pathway, costs, timing

Start a request for Abecma

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Join the Abecma waitlist

About Abecma

Oncology (MM)
Manufacturer: BMS/2seventy
Modality: CAR-T (BCMA)
Generic: idecabtagene vicleucel

Why Reserve Meds

DSCSA-compliant US sourcing. Physician-led. On-pathway in every destination. Patient-first intake with a named concierge.

Related

Access pathways
Country guidance
Articles & guides